CD80 and uveal melanoma: Since the antigens presented by the uveal melanoma vaccine cells are unknown, we determined TCR-Vβ usage of vaccine-activated CD4+ T cells upon repetitive stimulation with Mel202/DR1/CD80 vaccines.